CytomX Therapeutics
CTMX
113 hedge funds and large institutions have $264M invested in CytomX Therapeutics in 2019 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 39 increasing their positions, 33 reducing their positions, and 16 closing their positions.
856% more call options, than puts
Call options by funds: $86K | Put options by funds: $9K
25% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 16
18% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 33
4% more funds holding
Funds holding: 109 → 113 (+4)
0.25% more ownership
Funds ownership: 78.67% → 78.92% (+0.25%)
34% less capital invested
Capital invested by funds: $400M → $264M (-$135M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$8.67M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$6.28M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$2.29M |
| 4 |
Prudential Financial
Newark,
New Jersey
|
+$2.22M |
| 5 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$1.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$5.88M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.33M |
| 3 |
Millennium Management
New York
|
-$4.06M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.71M |
| 5 |
Morgan Stanley
New York
|
-$3.02M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PCM
126
Prelude Capital Management
New York
| – | -$7K | -611 | Closed |
|
127
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$2K | -210 | Closed |
|
|
PCP
128
Proficio Capital Partners
Newton,
Massachusetts
| – | -$2K | -142 | Closed |
|
|
SFSIG
129
San Francisco Sentry Investment Group
San Francisco,
California
| – | -$1K | -80 | Closed |
|
CTMX Hedge Fund Activity: Q3 2019 in Review
113 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q3 2019, worth a combined $264M — down 34% from $400M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new CTMX positions and 16 closed out — a net gain of 4 holders — while 39 added to existing stakes and 33 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $8.67M. The largest seller was T. Rowe Price Associates, cutting an estimated $5.88M.
- 113 institutional investors held CytomX Therapeutics (CTMX) as of Q3 2019, up from 109 in Q2 2019.
- Funds reported $264M of CytomX Therapeutics stock for Q3 2019, down 34% quarter-over-quarter.
- 20 funds opened new CytomX Therapeutics positions in Q3 2019 and 16 closed out, a net change of +4 holders.
- The largest CytomX Therapeutics buyer in Q3 2019 was Wellington Management Group, an estimated $8.67M added.
- The largest CytomX Therapeutics seller in Q3 2019 was T. Rowe Price Associates, an estimated $5.88M sold.
Based on aggregated 13F filings for Q3 2019.